• Disruptive Pharma agreed to sell its GTX platform to a wholly owned subsidiary of Aurelia Invest.
• Deal shifts all GTX-related rights and assets, including peptide programs based on A1M and lead candidate GTX-86.
• Consideration includes a modest upfront cash payment, described as not financially material.
• Future milestone payments tied to development and commercialization, including first-in-human dosing, pivotal-study dosing, marketing approval.
• Disruptive Pharma retains royalties, plus a share of proceeds from any future sale or out-licensing of the GTX platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disruptive Pharma AB (publ) published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.